Mauna Kea Technologies, page-6

I understand that Mauna Kea is undervalued given its cash burn and slow market penetration.
However the company has achieved €10m sales, the second-best year in its history, reduced its losses, targets significant markets like food intolerances, and has attracted major investors such as Johnson & Johnson and Telix, which are not charitable organizations. On the other hand, Optiscan barely makes any sales, lacks strategic pharmaceutical investors to validate its technology, yet it is valued five times higher. This suggests that either Optiscan is overvalued or Mauna Kea is undervalued. What do you think?